For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Royalty | - | - | - | 57,605 |
| Product | - | - | - | 118,329 |
| Total revenues | 272,551 | 164,677 | 211,007 | - |
| Collaboration And License Revenue | - | - | - | 2,941 |
| Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets | 28,028 | 5,350* | 15,781 | 11,420 |
| Total revenues | - | - | - | 178,875 |
| Amortization of acquired intangible assets | 11,581 | 9,349 | 7,534 | 4,061 |
| Total revenues-Manufacturing | - | - | - | 0 |
| Research and development | 100,873 | 133,128 | 100,158 | 112,990 |
| Selling, general and administrative | 86,183 | 96,874 | 84,046 | 85,262 |
| Change in the fair value of contingent consideration | - | -1,600* | - | - |
| Tangible asset impairment and losses on transactions, net | -927 | 10,275 | -472 | -99 |
| Total operating expenses | 227,592 | 236,026 | 207,991 | 213,832 |
| Income from operations | 44,959 | -71,349 | 3,016 | -34,957 |
| Interest expense, net | -49,030 | -55,188 | -32,592 | -30,358 |
| Other income (expense), net | 1,609 | -12,546 | 6,502 | -5,737 |
| (gain) income before income tax expense | -2,462 | -139,083 | -23,074 | -71,052 |
| Income tax expense | 347 | -4,118 | -38,970 | -6,203 |
| Net (gain) income | -2,809 | -134,965 | 15,896 | -64,849 |
| Basic EPS | -0.03 | -1.618 | 0.2 | -0.83 |
| Diluted EPS | -0.03 | -1.328 | 0.2 | -0.83 |
| Basic Average Shares | 82,521,023 | 83,398,965 | 78,471,119 | 78,151,240 |
| Diluted Average Shares | 82,521,023 | 101,593,445 | 87,115,369 | 78,151,240 |
PTC THERAPEUTICS, INC. (PTCT)
PTC THERAPEUTICS, INC. (PTCT)